Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic adipose-derived mesenchymal stem cells for refractory ischemic digital ulcers in systemic sclerosis
2023-508432-53-00Phase 2Authorised
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CSCC_ASC in systemic sclerosis (SSc), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoints: Proportion of refractory active ischemic digital ulcers healed without recurrence at 16 weeks and Composite healing and safety endpoint at 16 weeks. Planned start Sep 2020; status: authorised.
02
Drugs
CSCC_ASC
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2023-508432-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508432-53-00.